Medicines Distribution Consent




NEW ZEALAND GAZETTE

No. 41

Schedule

Name and Strength Form Name and Address of Manufacturer Proprietary Name (if any)
Clotrimazole 1% w/w Powder, topical Bayer AG., Leverkusen, Germany; Bayer Australia Limited, Mulgrave, Victoria, Australia; and Bayer SpA., Garbagnate, Milanese, Italy Canesten Broad Spectrum Antifungal Powder
Phytomenadione 10 mg/mL Injection, solution F Hoffmann-La Roche Limited, Basle, Switzerland Konakion MM Paediatric
Ethinyloestradiol 20 µg, levonorgestrel 100 µg Tablet, coated Schering AG., Wedding, Berlin, Germany Microgynon 20 ED

Dated this 26th day of March 1999.

GILLIAN GREW, Chief Advisor, Regulation and Safety (acting), pursuant to delegation given by the Minister of Health on the 20th day of February 1997.

go2429

Consent to the Distribution of a New Medicine

Pursuant to section 20 of the Medicines Act 1981, the Minister of Health hereby consents to the distribution in New Zealand of the new medicine set out in the Schedule hereto:

Schedule

Name and Strength Form Name and Address of Manufacturer Proprietary Name (if any)
Beclomethasone dipropionate 200 µg per metered dose Inhalation, powder Orion Corporation, Espoo, Finland Atomide Easyhaler
Oestradiol 0.312 mg/cm² (25 µg/24 hours) Transdermal patch 3M Pharmaceuticals, Northridge, California, United States of America Climara 25
Oestradiol 0.312 mg/cm² (75 µg/24 hours) Transdermal patch 3M Pharmaceuticals, Northridge, California, United States of America Climara 75
Dextromethorphan hydrobromide 1 mg/mL, Ammonium chloride 25 mg/mL, diphenhydramine hydrochloride 2.5 mg/mL Syrup PSM Healthcare Limited, Wiri, Auckland Dextromethorphan Cough Mixture
Dextromethorphan hydrobromide 1 mg/mL Syrup PSM Healthcare Limited, Wiri, Auckland Diphenhydramine Cough Mixture
Oestradiol hemihydrate 0.312 mg/cm² (25 µg/24 hours) Transdermal patch 3M Pharmaceuticals, Northridge, California, United States of America Femtran 25
Oestradiol hemihydrate 0.312 mg/cm² (75 µg/24 hours) Transdermal patch 3M Pharmaceuticals, Northridge, California, United States of America Femtran 75
Hydrocortisone 1% w/w, miconazole 2% w/w Cream, topical Ego Pharmaceuticals Pty Limited, Braeside, Victoria, Australia Fungocort
Opium tincture 1% 16.08 mg/mL, squill oxymel (as EFM oxymel squill 125:1000) 44.4 mg/mL Linctus PSM Healthcare Limited, Wiri, Auckland Gees Linctus
Morphine sulphate 10 mg Capsule, modified release Faulding Pharmaceuticals, Salisbury, South Australia, Australia Kapanol
Opti-Plus: Pancreatin equivalent to 950 µg tyrosine/min/mL, Opti-Free: Citric acid monohydrate 0.021% w/v, disodium citrate dihydrate 0.56% w/v, sodium chloride 0.516% w/v Solutions, contact lens Opti-Plus: Alcon Cusi SA., Alcobendas, Madrid, Spain; Opti-Free: Alcon Cusi SA., Alcobendas, Madrid, Spain; and Alcon Laboratories Inc., Fort Worth, Texas, United States of America Opti-Free / Opti-Plus Combination Pack
Paracetamol 500 mg Suppository Rice Steele & Co Limited, Tallaght, Dublin, Eire Paralink
Ranitidine hydrochloride 84 mg (equivalent to 75 mg ranitidine base) Tablet, film coated Glaxo Wellcome Operations, Ware, Hertfordshire, United Kingdom; and Glaxo Wellcome SA., Aranda de Duero, Spain Zantac 75

Dated this 26th day of March 1999.

GILLIAN GREW, Chief Advisor, Regulation and Safety (acting), pursuant to delegation given by the Minister of Health on the 20th day of February 1997.

go2430



Next Page →

PDF embedding disabled (Crown copyright)

View this page online at:


VUW Te Waharoa PDF NZ Gazette 1999, No 41


NZLII PDF NZ Gazette 1999, No 41





✨ LLM interpretation of page content

🏥 Consent to the Distribution of Changed Medicines

🏥 Health & Social Welfare
26 March 1999
Medicines Act 1981, Changed Medicines, Distribution Consent
  • GILLIAN GREW, Chief Advisor, Regulation and Safety (acting)

🏥 Consent to the Distribution of a New Medicine

🏥 Health & Social Welfare
26 March 1999
Medicines Act 1981, New Medicine, Distribution Consent
  • GILLIAN GREW, Chief Advisor, Regulation and Safety (acting)